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Genetic analyses of cancer progression in patient samples and model systems have thus
far failed to identify specific mutational drivers of metastasis. Yet, at least in experimental
systems, metastatic cancer clones display stable traits that can facilitate progression
through the many steps of metastasis. How cancer cells establish and maintain the tran-
scriptional programmes required for metastasis remains mostly unknown. Emerging evi-
dence suggests that metastatic traits may arise from epigenetically altered
transcriptional output of the oncogenic signals that drive tumour initiation and early pro-
gression. Molecular dissection of such mechanisms remains a central challenge for a
comprehensive understanding of the origins of metastasis.
ª 2016 The Author(s). Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).While primary tumours can often be surgically removed, me-
tastases are in most cases incurable. The formation of metas-
tases in distant organs thus represents one of the most
devastating aspects of cancer. Large-scale cancer genome pro-
jects have recently catalogued the mutational complements
ofmost human tumours. However, mutations that specifically
drive metastatic progression have not been identified. On the
other hand, experimental approaches have isolated stable
cancer clones that express transcriptional traits associated
with metastasis. Many genes have been functionally linked
to metastatic progression and several studies have described
in detail diversemolecular mechanisms that, in different con-
texts, endow cancer cells with properties that modulate the
rate of metastatic success (Massague and Obenauf, 2016;
Oskarsson et al., 2014; Valastyan andWeinberg, 2011). Specific
phenotypic traits, dictated by the expression of specific mole-
cules, thus mediate metastatic cancer progression. Little,(S. Vanharanta).
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9.008however, is known about the mechanisms through which
cancers acquire metastatic traits. Using specific examples,
this review will discuss a model whereby metastatic tran-
scriptional programmes emerge from epigenetic optimization
of the oncogenic signals that drive tumour initiation and early
progression.1. The metastatic process
Metastases arise through a complex evolutionary process
through which cells from a primary tumour eventually form
clinically detectable secondary tumours in distant organs.
This process is extremely inefficient. The vastmajority of can-
cer cells never leave the primary tumour, and of those that
manage to enter the circulation, the vast majority fail to enter
distant organs (Baccelli et al., 2013; Kienast et al., 2010; Luzziof Federation of European Biochemical Societies. This is an open
censes/by/4.0/).
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ses, only a small fraction forms clinically relevant metastatic
lesions (Braun et al., 2005). Hence, even though often depicted
as an orderly sequence of distinct biological steps (Fidler,
2003), metastatic progression is characterized by extreme
randomness whereby potentially millions of circulating
tumour cells dispatched over several years in the end only
form few metastases (Vanharanta and Massague, 2013).
Several distinct barriers for metastatic progression exist. In a
simple example, tumour cells originating from epithelia will
first have to detach from their native tissue structure, invade
the nearby parenchyma, enter the circulation through intra-
vasation, sustain circulatory stress, enter a distal organ
through extravasation, survive upon arrival at the distant
site, co-opt the new microenvironment and eventually estab-
lish a secondary colony. Additionally, more complicated sce-
narios can, for example, involve initial invasion and entry
into the circulation via the lymphatic system, intermediate
metastases in lymph nodes or other sanctuary sites and vary-
ing lengths of cellular dormancy of single disseminated cells
or micro metastases. Molecular mechanisms that mediate
many of these steps have been identified in experimental sys-
tems (Massague and Obenauf, 2016; Oskarsson et al., 2014;
Valastyan and Weinberg, 2011), and inhibition of a vast array
of genes that encode for proteinswith variousmolecular func-
tions can inhibitmetastatic progression. The picture emerging
from these studies is that metastasis genes do not seem to
operate through a shared molecular pathway. Rather, they
represent a heterogeneous group of metastasis facilitators
that enhance the probability of successful completion of one
or more of the metastatic steps via modulating the activity
of the oncogenic pathways that also drive the earlier steps
of tumorigenesis. How the expression of these traits is regu-
lated remains largely unknown.2. Mutational drivers of metastasis
The inefficiency and distinct biological barriers of metastasis
would a priori seem to generate an ideal playground for selec-
tion to enrich for mutations that confer metastatic capabil-
ities. Indeed, the early genetic models of cancer progression
suggested that metastases would be caused by specific muta-
tions (Fearon and Vogelstein, 1990; Nowell, 1976). However,
despite extensive efforts, such mutations have not been iden-
tified to date (Turajlic and Swanton, 2016; Vogelstein et al.,
2013). Metastatic cancer clones when compared to the corre-
sponding primary tumour do in most cases contain unique
mutations, some of which are predicted to be drivers, but
these target genes are alreadymutated in the primary tumour
in other contexts. For example, in pancreatic (Yachida et al.,
2010), renal (Gerlinger et al., 2012) and breast (Yates et al.,
2015) cancers, distinct clones already present in the primary
tumour can be the sources ofmetastases to different target or-
gans. In prostate cancer (Gundem et al., 2015) and melanoma
(Sanborn et al., 2015), metastatic clones were shown to origi-
nate from specific regions of the corresponding primary tu-
mours with sometimes complex relationships between
different distant sites, arguing for both parallel and step-
wise seeding of metastases as well as continuous seeding ofPlease cite this article in press as: Patel, S.A., Vanharanta, S., Epige
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hand, in colon cancer, fewmetastasis-specificmutationswere
detected (Jones et al., 2008). Finally, a large study comparing
metastatic lesions to the corresponding primary tumours
from several different cancer types revealed examples of
mutational selection during cancer progression, possibly
imposed by metastatic bottlenecks and therapies, but no uni-
fying genetic signature of metastasis was identified
(Brastianos et al., 2015). Some evidence suggests that TP53mu-
tations could be important for the emergence of metastatic
cancer clones, possibly through effects on genome stability
(Turajlic and Swanton, 2016). However, even histologically
normal skin can harbour TP53 mutant clones (Martincorena
et al., 2015).
Results from experimental metastasis models are in agree-
ment with the data from clinical samples. For example, in
genetically engineered mouse models of lung and pancreatic
cancer, both parallel and polyclonal seeding of metastases
have been observed but the authors did not report enriched
mutations in specific genes in the metastatic clones
(Maddipati and Stanger, 2015; McFadden et al., 2014). Also,
human-derived cancer clones with functionally confirmed
metastatic potential can display minimal genetic divergence
from the non-metastatic parental population (Jacob et al.,
2015), suggesting that the development of metastatic clones
from already advanced cancers may not need additional
mutations.
From a genetic point of view, no unifying model for meta-
static progression thus seems to exist. The reasons for this
remain unknown, but several possible explanations have
been proposed, including technical issues related to mutation
detection and lack of sufficient sample size, the low probabil-
ity of specific mutations to generate complex phenotypes
needed for metastatic competence, and the requirement of
already maximal fitness for the development of advanced
cancers, after which stochastic metastases would follow
without the need for further genetic changes (Frost and
Fidler, 1986; Vogelstein et al., 2013). It remains possible that
further genetic analyses will identify metastasis mutations,
at least in some cancers, but accumulating data suggest that
suchmutations may not be the dominant route for the activa-
tion of metastatic traits.3. Epigenetic instability and metastatic progression
If not via genetic alterations, how do cancers acquiremetasta-
tic traits? Two general possibilities exist. On the one hand, it
may be that no stable traits that drive metastases exist. This
view is supported by evidence showing that even metastatic
cells can be reprogrammed by embryonic microenviron-
ments, suggesting that at least some of the metastatic traits
are reversible and thus most likely not dictated by mutations
(Hendrix et al., 2007). There is also some evidence for reversal
of the aggressive phenotype in lung metastatic foci (Bockhorn
et al., 2014). On the other hand, at least in experimental sys-
tems, stable highly metastatic cancer cell populations with
limited genetic divergence from the parental population can
be isolated and they express genes that are highly active in pa-
tient samples with higher propensity to metastasize,netic determinants of metastasis, Molecular Oncology (2016),
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are also present in human tumours (Bos et al., 2009; Jacob
et al., 2015; Minn et al., 2005; Vanharanta et al., 2013). Many
of these genes have been functionally linked to metastatic
progression (Massague and Obenauf, 2016; Oskarsson et al.,
2014; Valastyan and Weinberg, 2011). This, together with the
lack of genetic evidence for metastasis driver mutations, sug-
gests that heritable non-genetic, i.e. epigenetic, transcrip-
tional programmes underlie metastatic cancer progression.
Several possible molecular mechanisms of epigenetic in-
heritance have been proposed. The best characterized of these
is DNA cytosinemethylation, the addition of amethyl group to
form 5-methylcytosine (5mC) at CpG dinucleotides, for which
a clear mechanism of inheritance through cell division has
been identified (Song et al., 2011). Thus, once DNA methyl-
ation patterns have been established by a given signal, usually
guided by transcription factors with sequence specific DNA-
binding properties (Sch€ubeler, 2015), thesemarks can be prop-
agated in the absence of the initial stimulus. Conversely, if
DNA methylation is lost, either through active or passive
demethylation, critical DNAmethylationmarks can be altered
permanently. Modifications of other deoxynucleotides also
exist in human cells, but their relevance to epigenetic inheri-
tance remains to be established (Koziol et al., 2016). Covalent
modifications of the histones represent a second class of mo-
lecular alterations that contributes to the maintenance of sta-
ble transcriptional programmes (Jenuwein and Allis, 2001).
However, unlike DNA methylation, it remains unclear how
most of these marks are maintained during replication.
Less-well characterized mechanisms involving non-coding
RNAs also contribute to epigenetic gene regulation (Sabin
et al., 2013). Finally, stable transcriptional programmes can
be supported without any specific heritable changes in DNA
methylation or chromatin by autoregulatory transcriptional
circuits that after being inducedmaintain their own transcrip-
tion (Ptashne, 2007). Identification of such feed-forward loops
as mediators of metastasis is challenging as they can be
induced by transient stimuli that may not be present in full-
blown tumours. Yet, they could be critical for the mainte-
nance of cancer phenotypes.4. DNA methylation
DNA methylation is usually associated with transcriptional
silencing (Sch€ubeler, 2015). In cancer, widespread hypome-
thylation is generally observed with only specific regions
such as CpG islands being hypermethylated (Berman et al.,
2012; Hansen et al., 2011). Similar observations have been
made in many if not most cancer types (Feinberg and Tycko,
2004). Oncogene (e.g. HRAS ) promoter regions are frequently
hypomethylated (Feinberg and Vogelstein, 1983), while
tumour suppressor loci such as TP53, APC and VHL are
commonly hypermethylated in association with transcrip-
tional silencing (Herman and Baylin, 2003), suggesting that
DNA methylation alterations at specific loci can influence
tumour progression. The functional relevance of the more
widespread DNA hypomethylation in cancer is unknown,
but it has been suggested to induce genomic instability
(Jones and Gonzalgo, 1997). DNA methylation patterns havePlease cite this article in press as: Patel, S.A., Vanharanta, S., Epige
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DNA methylation is in general well conserved between pri-
mary and corresponding metastatic tumours (Aryee et al.,
2013), whereas in breast cancer, others have observed
metastasis-specific methylation changes, primarily outside
CpG-rich regions (Reyngold et al., 2014). In prostate cancer,
there is also considerable intratumoural DNA methylation
heterogeneity that correlates well with genomic copy number
patterns andmetastatic progression (Brocks et al., 2014). Thus,
there is a significant body of evidence that links aberrations in
DNAmethylation to tumourigenesis. However, the interpreta-
tion of these data is complicated by the observation that the
DNA methylation status of promoter CpG islands in a given
tumour type tends to reflect the pattern observed in the corre-
sponding tissue of origin (Gebhard et al., 2010; Sproul et al.,
2012; Sproul and Meehan, 2013; Timp and Feinberg, 2013).
Several examples link aberrations in DNA methylation to
the acquisition of functionally important metastatic traits
(Figure 1). In renal cell carcinoma (RCC), increased global
DNA methylation is associated with poor patient outcome
(The Cancer Genome Atlas Network, 2013). However, experi-
mental analysis has identified functional mediators of RCC
metastasis that are activated via DNA demethylation events.
For example, cytohesin 1 interacting protein (CYTIP) and
S100 calciumbinding protein A4 (S100A4) are highly expressed
and demethylated inmetastatic RCC subpopulations and they
functionally mediate metastatic colonization (Lopez-Lago
et al., 2010; Vanharanta et al., 2013). Additionally, hyperme-
thylation of the CYTIP locus is associated with good patient
survival (Gevaert et al., 2015). Without an active transcrip-
tional programme, loss of DNA methylation does not lead to
gene activation. Indeed, CYTIP expression is driven by the
RCC-initiating VHL-HIF pathway (Figure 1A) (Vanharanta
et al., 2013). A similar mechanism has been implicated inmel-
anoma progression, whereby loss of DNA methylation facili-
tates the expression of a variant transcript of the Rab
GTPase-activating protein TBC1D16 in support of metastasis
(Vizoso et al., 2015). Once released by repression of DNA
methylation, TBC1D16 expression is driven by the core mela-
nocyte lineage factor MITF (Figure 1B). DNA hypomethylation
has also been linked to osteosarcoma metastasis through the
induction of IRX1, however the pathway that drives gene
expression in this case remains unidentified (Lu et al., 2015).
In these examples, the mechanism through which DNA
methylation is lost remains unknown. It could be through pas-
sive stochastic dilution of methylated CpGs during cell divi-
sion, but accumulating evidence suggests that active DNA
demethylation can also be involved in the acquisition of inva-
sive and metastatic phenotypes (Munoz et al., 2013).
DNA methylation can also silence metastasis suppressor
genes. Global profiling of matched cell lines from metastasis
and primary tumour identified CDH11 as a target of silencing
via DNAmethylation and subsequent functional analysis sup-
ported a role for CDH11 in metastasis suppression (Carmona
et al., 2012). Similarly, several microRNAs have been shown
to undergo methylation-dependent silencing in metastatic
cancer (Lujambio et al., 2008). The genomic locus for the
metastasis suppressor miR-335 is epigenetically silenced and
subsequently also deleted inmetastatic breast cancer; howev-
er, this is through maternal imprinting (Png et al., 2011).netic determinants of metastasis, Molecular Oncology (2016),
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Figure 1 e Alterations in DNA methylation patterns as a source of cancer progression traits. (A) Loss of DNA methylation expands the HIF2A
tumour-initiating pathway output in renal cell carcinoma (RCC) to promote metastasis. In the presence of oxygen, HIF2A is normally targeted for
proteosomal degradation, but in VHL mutant RCC cells HIF2A is constitutively expressed and it drives tumorigenesis. DNA demethylation in
metastatic cells increases the HIF2A pathway target gene spectrum to include pro-metastatic CYTIP expression. (B) Melanocyte lineage factor
MITF signalling output is expanded through DNA demethylation in support of metastatic progression in melanoma. MITF drives differentiation/
pigmentation and proliferation/survival in melanocyte and melanoma cells. Loss of DNA methylation allows MITF to bind additional gene
promoters and induce expression of metastasis-promoting TBC1D16. (C) Metabolic alterations can induce global alterations in DNA methylation.
In glioblastoma, IDH1/2 mutants produce the oncometabolite 2-hydroxyglutarate (2-HG) which inhibits the activity of TET enzymes. TETs
normally mediate demethylation of DNA by converting 5-methylcytocine (5mC) to 5-hydroxymethylcytosine (5hmC). Thus, the accumulation of
2-HG leads to increased DNA methylation resulting in the global CpG island hypermethylator phenotype (CIMP). This can lead to tumour
suppressor silencing or loss of the binding of methylation sensitive DNA-binding factors such as CTCF. CTCF functions as an insulator protein
that demarcates chromatin domains. In glioblastoma, CIMP-induced loss of CTCF binding can allow aberrant PDFGRA activation. Thus,
unspecific large-scale alterations in DNA methylation can result in specific cancer phenotypes. Similar mechanism could activate metastasis genes
as well.
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but rather, the silencing of a gene during development serves
essentially as the first inactivating hit of a tumour suppressor.
A CpG island methylator phenotype (CIMP) has been
described in many cancer types (Issa, 2004). Analysis of hu-
man data sets have demonstrated that in some cancers,
such as prostate cancer, CIMP is associatedwith poor outcome
(Gu et al., 2015), whereas in others, such as breast cancer and
glioblastoma, CIMP seems to correlate with increased patient
survival (Fang et al., 2011; Turcan et al., 2012), possibly
because CIMP-induced stable gene repression may reduce
the probability of the acquisition of aggressive cancer pheno-
types (Sproul and Meehan, 2013). In glioblastoma, CIMP hasPlease cite this article in press as: Patel, S.A., Vanharanta, S., Epige
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in the tricarboxylic acid cycle (TCAC) enzyme isocitrate dehy-
drogenase (IDH1) (Turcan et al., 2012). In this model, increased
levels of the oncometabolite 2-hydroxyglutarate inhibit the
activity of the TET enzymes that are important for the conver-
sion of 5mC to 5-hydroxymethylcytosine (5hmC), an interme-
diate step for active demethylation, thus leading to global
increase in DNA methylation (He et al., 2011; Xu et al., 2011)
(Figure 1C). Interestingly, DNA methylation in this context
can change the affinity of the chromatin insulator protein
CTCF to specific target loci, leading to altered chromatin
domain structure and activation of oncogenic drivers such
as PDGFRA (Flavahan et al., 2016). The extent to which similarnetic determinants of metastasis, Molecular Oncology (2016),
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including metastasis, remains unclear, but there is evidence
that CTCF/cohesin binding sites can accumulate mutations
in several cancers (Katainen et al., 2015). In addition to IDH1,
loss of other TCAC enzymes such as FH and SDH can also
induce aberrant DNA methylation patterns (Letouze et al.,
2013; Sciacovelli et al., 2016), and microenvironmental factors
such as hypoxia can lead to global DNA hypermethylation
with possible cancer promoting consequences (Thienpont
et al., 2016). As shown in breast cancer, microRNA-mediated
silencing of TET enzymes can similarly lead to changes in
DNA methylation and consequent activation of metastasis
genes (Song et al., 2013). In breast cancer, widespread DNA
methylation that promotes metastasis may also be induced
by receptor tyrosine kinase activation and consequent induc-
tion of the methyl-CpG binding domain protein 4 (MBD4)
(Cunha et al., 2014). On the other hand, in prostate cancer,
CIMP has been linked to an increased activity of the chromatin
reader BAZ2A that interacts with the Polycomb Repressive
Complex 2 (PRC2) (Gu et al., 2015). Finally, in colorectal cancer
oncogenic KRASG13D seems to maintain CIMP and consequent
suppression of tumour suppressors through the expression of
sequence specific DNA-binding proteins and associated mod-
ulators of gene repression (Serra et al., 2014), demonstrating
that specific signalling pathways can also induce global
changes in DNA methylation.
It is unclear what mechanisms target DNA methylation or
demethylation events to specific loci duringmetastatic cancer
progression. The activation of oncogenic pathways can target
DNA methyltransferases to tumour suppressor loci and at
least in some cases, active signalling is required for the main-
tenance of gene silencing and DNA methylation (Gazin et al.,
2007; Serra et al., 2014). It could be that DNA methylation
changes in metastasis also reflect alterations in the activities
of transcription factors that have DNA-binding specificities.
Indeed, experimental evidence suggests that DNA sequences
play an instructive role in determining DNA methylation pat-
terns in normal cells (Krebs et al., 2014). However, the role of
local sequence characteristics in determining the DNA
methylation status in cancer is less clear (Krebs et al., 2014)
and specific pro-metastatic changes could also emerge from
the stochastic alterations in global DNA methylation patterns
through selection (Hansen et al., 2011; Landan et al., 2012;
Timp and Feinberg, 2013).5. Chromatin alterations
While there is evidence that transcription factors determine
the genomic distribution of tissue specific histone marks
(Benveniste et al., 2014), at least some repressive histone
modifications seem to be heritable through the cell cycle
(Hansen et al., 2008; Hathaway et al., 2012; Margueron
et al., 2009). Stable chromatin alterations could therefore
be another way for cancer cells to lock in metastatic pheno-
types. The frequent mutations in various chromatin factors
and histones in cancer have indisputably linked chromatin
biology to tumorigenesis (Shen and Laird, 2013). Mutations
in some of these genes, such as PBRM1 and BAP1 in renal
cell carcinoma, are associated with poor patient outcomePlease cite this article in press as: Patel, S.A., Vanharanta, S., Epige
http://dx.doi.org/10.1016/j.molonc.2016.09.008(Joseph et al., 2016; Pawlowski et al., 2013), indicating that
their downstream pathways may also contribute to cancer
progression and metastasis.
5.1. The Polycomb Repressive Complex 2
The Polycomb Repressive Complex 2 (PRC2) is a critical regu-
lator of gene repression in multiple biological contexts
(Margueron and Reinberg, 2011). It consists of three core
subunits, EED, SUZ12, the catalytic subunit EZH1/EZH2,
and several associated factors. EZH1/EZH2 can deposit tri-
methylation marks on histone H3 lysine 27 (H3K27me3),
which can be recognized by the chromatin reader subunit
EED (Margueron et al., 2009). This is thought to allow the
mark to be propagated through cell division. There is evi-
dence that deposition of PRC2 at given genomic loci is pas-
sive: inactive promoters naturally acquire PRC2 and
H3K27me3, which then stabilizes the inactive state
(Jermann et al., 2014; Riising et al., 2014) (Figure 2A). Inter-
estingly, both activating and inactivating mutations in
EZH2 have been identified in different cancers (Cerami
et al., 2012; Ernst et al., 2010; McCabe et al., 2012;
Souroullas et al., 2016). Moreover, EZH2 is often upregulated
in various cancers and the expression of EZH2 often corre-
lates with poor patient outcome (Chase and Cross, 2011;
Chen et al., 2015); although this could, at least in some
cases, be simply reflecting the higher proliferative pheno-
type associated with cancer progression (Wassef et al.,
2015). However, EZH2 activity is critical for EMT in breast
cancer (Malouf et al., 2013; Tiwari et al., 2013) and metastatic
progression of melanoma (Zingg et al., 2015). Similarly,
EZH2-mediated silencing of a Ras GTPase-activating protein
enhances RAS and NF-kappaB signalling in metastatic pros-
tate cancer (Min et al., 2010). On the other hand, loss of PRC2
activity has also been linked to metastatic progression. For
example, expression of the chemokine receptor CXCR4 is
suppressed by PRC2 in renal cell carcinoma, and loss of
this suppression facilitates CXCR4 expression and increases
the metastatic fitness of RCC cells (Vanharanta et al., 2013).
In this case, CXCR4 expression is also dependent on the ac-
tivity of the VHL-HIF pathway that drives RCC induction and
early progression, yet HIF2A activity alone is not sufficient
for CXCR4 expression. What leads to PRC2 eviction from
the CXCR4 locus during RCC progression remains unknown,
but it is noteworthy that low global levels of H3K27me3
seem to be associated with poor patient outcome in RCC
(Rogenhofer et al., 2012). PRC2 loss can also potentiate onco-
genic RAS signalling in specific genetic contexts, leading to
potential therapeutic vulnerabilities (De Raedt et al., 2014).
Interestingly, even transient reduction of PRC2 activity can
induce stable expression of its target genes, suggesting
that PRC2 loss can promote epigenetic instability that may
contribute to cancer progression (Wassef et al., 2015). Anal-
ogously, PRC2 inhibition can support the emergence of drug
resistant cancer clones (Rathert et al., 2015). Thus, while
PRC2 function in some cancers seems to be critical for the
suppression of genes that inhibit metastasis, there is also
strong evidence that loss of PRC2 promotes metastasis in
other contexts, possibly by increasing transcriptional plas-
ticity (Figure 2B).netic determinants of metastasis, Molecular Oncology (2016),
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SWI/SNF is amulti-subunit ATP-dependent chromatin remod-
elling complex that plays a critical role in several develop-
mental processes (Wilson and Roberts, 2011). In humans,
there are 29 genes that encode the 15 SWI/SNF subunits in a
partially tissue specific manner (Kadoch and Crabtree, 2015).
Strikingly, >20% of cancers carry mutations in SWI/SNF com-
plex genes, making it the most frequently mutated chromatin
regulatory pathway in human cancer (Kadoch et al., 2013). The
mutations show strong tissue specificity, indicating that
different SWI/SNF variants modulate the transcriptional
output of tissue specific oncogenic and tumour suppressive
pathways. Most SWI/SNF mutations seem to be inactivating
(Kadoch and Crabtree, 2015). Interestingly, mutations in SWI/
SNF complex members may result in specific molecular vul-
nerabilities that could be exploited therapeutically (Bitler
et al., 2015; Helming et al., 2014). While the genetic evidence
linking SWI/SNF dysregulation to carcinogenesis is strong,
fairly little is known about the mechanisms that link SWI/
SNF to tumorigenesis. Similarly, it remains unclear how SWI/
SNF alterations contribute to metastasis. In renal cell carci-
noma, data from multi-region tumour sequencing suggest
thatmutations in theSWI/SNFmemberPBRM1occurearlydur-
ing tumorigenesis (Gerlingeret al., 2014). Yet,PBRM1mutationsPlease cite this article in press as: Patel, S.A., Vanharanta, S., Epige
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mours (Pawlowski et al., 2013), suggesting that PBRM1 may
modulate the probability of RCC cells acquiring metastatic
traits at a later stage of tumour progression. Conversely,
some evidence suggests that in breast cancer SWI/SNF activity
may promote metastatic progression (Wang et al., 2014).
5.3. Other chromatin factors
In addition to the Polycomb and SWI/SNF complexes, multiple
other chromatin regulators have been linked to metastatic
progression. For example, the inhibitory nuclear corepressor
1 (NCoR), a member of histone deacetylase (HDAC) complexes
that is known to suppress nuclear receptor activity, sup-
presses metastatic hepatocellular carcinoma progression by
inhibiting the expression of multiple metastasis genes
(Martinez-Iglesias et al., 2016). Similarly, the related members
of another HDAC complex, BRMS1 and BRMS1L, inhibit breast
cancermetastasis by suppressingmultiple transcriptional tar-
gets (Gong et al., 2014; Hurst, 2012). The histone H3 lysine 4
demethylase LSD1, a member of the multifunctional nucleo-
some remodelling and deacetylase (NuRD) complex, can also
inhibit metastasis (Wang et al., 2009). A more specific metas-
tasis suppressive role has been described for the (NAD)þ-
dependent histone deacetylase SIRT6 in pancreatic ductalnetic determinants of metastasis, Molecular Oncology (2016),
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seem to be largely mediated through induction of the RNA-
binding protein Lin28b. Tumours with low SIRT6 expression
are highly dependent on Lin28b, highlighting the interesting
possibility that changes in the activity of specific HDACs could
lead to cancer cell dependencies with therapeutic potential
even in the metastatic setting. On the other hand, other
HDACs, such as SIRT1, have positive effects onmetastatic pro-
gression in prostate cancer (Byles et al., 2012). While these ex-
amples clearly demonstrate the relevance of HDAC complexes
for metastatic cancer progression, they also highlight the
context specific nature of HDAC phenotypes.
In addition to LSD1, several other histone demethylases
and methyltransferases have been implicated in metastatic
cancer progression. Activation of the histone H3 lysine 9
demethylase PHF2 can lead to mesenchymal-to-epithelial
transition (MET), i.e. the reversal of EMT, thus leading to
reduced tumour-initiating capacity in breast cancer
(Pattabiraman et al., 2016). Histone H3 lysine 4 demethylase
KDM5A is critical for breast cancer progression andmetastasis
by facilitating the expression TNC and other genes, but the
mechanism is independent of the demethylase activity of
KDM5A (Cao et al., 2014). KDM2A demethylates H3K36me2 in
lung cancer, which reduces the expression of several genes
such as HDAC3 and DUSP3 leading to increased invasiveness
(Dhar et al., 2014; Wagner et al., 2013). JMJD2C/KDM4C inter-
acts with HIF1A to enhance target gene activation and pro-
mote breast cancer progression and metastasis by
demethylating H3 lysine 9 near several HIF1A target genes
(Luo et al., 2012). The H3K79 methyltransferase DOT1L pro-
motes breast cancer metastasis by activating many EMT me-
diators in collaboration with c-MYC (Cho et al., 2015). The
H3K4 methyltransferases KMT2A and KMT2B, both members
of the MLL complex, collaborate with the androgen receptor
to promote prostate cancer progression (Malik et al., 2015).
Finally, altered expression of histones has been linked to met-
astatic progression; the histone variant macroH2A inhibits
melanoma progression through suppression of CDK8 expres-
sion (Kapoor et al., 2010).
Collectively these selected examples highlight the fact that
alterations in the activity of various different chromatin regu-
lators that lack DNA-binding specificities are functionally
linked to metastatic progression. While for some of them a
transcriptional programme that confers specificity has been
identified, in many cases it is unclear why a particular chro-
matin regulator is important in a given cancer context. How-
ever, the emerging picture suggests that chromatin factor
specificity in different metastatic phenotypes is likely to
reflect the underlying oncogenic driver pathways. As many
chromatin factors are potentially druggable, it is of significant
interest to identify the chromatin regulatory dependencies of
the core oncogenic programmes that drive metastasis in
different cancers.6. Long non-coding RNAs
Long non-coding RNAs (lncRNAs) are emerging as important
regulators of various biological processes, including chro-
matin remodelling and DNA methylation (Sabin et al., 2013).Please cite this article in press as: Patel, S.A., Vanharanta, S., Epige
http://dx.doi.org/10.1016/j.molonc.2016.09.008Increasing evidence is also supporting their role in the control
of metastatic progression. For example, HOX transcript anti-
sense RNA (HOTAIR) is strongly upregulated in breast tu-
mours, and it is a powerful predictor of subsequent
metastasis and death (Gupta et al., 2010). HOTAIR binds
directly to PRC2 and LSD1 inducing their genome-wide retar-
geting and an altered gene expression profile in cancer cells
(Gupta et al., 2010; Tsai et al., 2010) (Figure 3A). In prostate can-
cer, high expression of the lncRNA SChLAP1 correlates with
aggressive tumour phenotypes and metastasis, and experi-
mental evidence suggests that SChLAP1 antagonizes the
tumour suppressive functions of the SWI/SNF complex
(Prensner et al., 2013) (Figure 3B). In metastatic non-small
cell lung cancer, increased expression of metastasis-
associated lung adenocarcinoma transcript-1 (MALAT1) corre-
lates with poor prognosis (Ji et al., 2003) and inhibition of
MALAT1 expression reduces lung cancer metastasis
(Gutschner et al., 2013). Additionally, lncRNA BCAR4 controls
the epigenetic regulation of Hedgehog/GLI2 transcriptional
activation in support of breast cancer progression (Xing
et al., 2014), whereas CCAT2modulatesWNT andMYC activity
in colon cancer leading to increased metastasis (Ling et al.,
2013) (Figure 3C). Non-coding enhancer RNAs (eRNAs) are
also emerging as important regulators of oncogenic signalling
(Li et al., 2013), but their role in metastasis remains unex-
plored. Current evidence thus has implicated several lncRNAs
in metastasis, and evidence from other contexts suggests that
lncRNAs can influence the epigenetic machinery. Also,
through sequence complementarity with DNA or nascent
RNA, lncRNAs could in principle direct epigenetic regulators
to specific genomic loci. If and how such mechanism affect
the epigenetic inheritance of stable metastatic traits is an
interesting avenue for future exploration.7. Autoregulatory transcriptional circuits
As demonstrated by cellular reprogramming experiments, self-
sustaining transcriptional networks define cell identities
(Hochedlinger and Jaenisch, 2015). Different tissues, including
cancers, are thus characterized by unique gene expression pro-
files and chromatin landscapes (Hnisz et al., 2013). Accordingly,
sporadic cancers arising in different tissues harbour distinct
patterns of mutations (Vogelstein et al., 2013), and germline
mutations in hereditary cancer syndromes predispose to spe-
cific tumour types (Vogelstein and Kinzler, 1998). Hence, while
mutations can dictate cancer phenotypes, gene regulatory pat-
terns can determine whether or not specific mutations confer
selective advantage. In general, little is known about the tran-
scriptional programmes that define cell states in most cancer
types. However, several predictions have been made (Saint-
Andre et al., 2016) and some have been functionally character-
ized. In glioblastoma, functional dissection of tumour initiation
potential revealed a transcriptional network consisting of four
transcription factors, OLIG2, POU3F2, SALL2 and SOX2, as crit-
ical enforcers of stem cell identity (Suva et al., 2014). These fac-
tors were expressed in a substantial proportion of glioblastoma
cells from patient samples, suggesting that the core transcrip-
tional network of glioblastomas was not a feature of rare can-
cer stem cells (Patel et al., 2014). In T-cell acute lymphoblasticnetic determinants of metastasis, Molecular Oncology (2016),
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Figure 3 e Long non-coding RNAs in the epigenetic regulation of metastasis. (A) LncRNAHOTAIR found in breast cancer metastasis binds and
activates PRC2 and LSD1 to remodel the histone methylation landscape. This can induce a pro-metastatic gene expression profile. (B) SChLAP1
lncRNA expression is found in metastatic prostate cancer cells. Mechanistically, SChLAP1 binds and antagonizes SNF5, a component of the
SWI/SNF complex. (C) CCAT2 is transcribed from the enhancer region 335 kb upstream ofMYC. Accumulation of CCAT2 in metastatic colon
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interaction upstream of MYC to increase MYC expression in metastatic cells.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 6 ) 1e1 68leukemia (T-ALL), specific non-coding mutations upstream of
the TAL1 oncogene are capable of generating a self-sustaining
transcriptional loop, which involves several T-ALL transcrip-
tion factors such as MYB, GATA3, RUNX1 and TAL1 itself
(Mansour et al., 2014). Interestingly, cancer-defining transcrip-
tional programmes can be extremely sensitive to perturbations
in the activity of specific transcription factors or chromatin
binding proteins (Loven et al., 2013). For example, in acute
myeloid leukaemia, both enhanced and reduced activity of crit-
ical transcriptional regulators, such as IRF8, CEBPA, ETV6 and
FOSL2, and the inhibition of the broadly targeted chromatin
reader BRD4 reduce cellular fitness (Pelish et al., 2015; Zuber
et al., 2011). Several transcription factors have also been linked
to either increased or decreased metastatic propensity (Brady
et al., 2016; Cheung et al., 2013; Denny et al., 2016; Winslow
et al., 2011). It is possible that these or other factors contribute
to transcriptional circuits that could autonomously maintain
metastatic transcriptional programmes. Some studies have
indeed explored this possibility (Lee et al., 2014), but the extent
and nature of such mechanisms as regulators of metastatic
progression remain mostly unknown.8. Oncogenic pathways as drivers of metastasis
As can be seen from the examples above, epigenetic alter-
ations are intimately linked to metastasis. However, there is
no general pattern that would universally connect a specificPlease cite this article in press as: Patel, S.A., Vanharanta, S., Epige
http://dx.doi.org/10.1016/j.molonc.2016.09.008epigenetic modality to metastatic progression; each regulato-
ry mechanism can either promote or inhibit metastasis
depending on the context. This is logical, as the epigenetic
regulatory mechanisms are general modifiers of gene expres-
sion and their target genes are dependent on the transcrip-
tional state of the cell. Thus, the epigenetic modifications
that promote metastatic progression do so by modifying the
output of the already activated transcriptional programmes
(Figure 4). The drivers of these programmes are either acti-
vated specifically in the cancer cells through oncogenic muta-
tions, or they represent endogenous linage and other factors
that are induced without cancer-specific oncogenic alter-
ations. Examples of both have been described. Tumour-initi-
ating mutations in VHL lead to the activation of the
transcription factor HIF2A, but this does not automatically
lead to the acquisition of a metastatic phenotype. However,
epigenetic modulation of the HIF2A transcriptional output
can later on lead to the expression of pro-metastatic genes
(Vanharanta et al., 2013). On the other hand, the hormone-
dependent transcription factor networks that are critical for
the normal development and homoeostasis of the breast
and prostate epithelium, respectively, drive the expression
of pro-metastatic genes in advanced cancers arising in these
tissues (Goodwin et al., 2015; Ross-Innes et al., 2012). Similarly,
the transcriptional output of the linage factor MITF is epige-
netically modulated in support of melanoma progression
(Vizoso et al., 2015). Most epigenetic alterations associated
with metastatic progression seem to operate in an analogousnetic determinants of metastasis, Molecular Oncology (2016),
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Figure 4 e Optimization of oncogenic signal output facilitates metastatic cancer progression. Thus far, no metastasis-specific genetic pathways
have been identified. This suggests a model whereby metastatic progression is supported by the same oncogenic pathways that drive tumour
initiation and early progression. However, the output of these pathways is not constant but evolves during cancer progression in support of the
most aggressive tumour phenotypes. In a mutually non-exclusive manner, this modulation of pathway output can be both quantitative and
qualitative. For example, during metastatic progression a given pathway may become more active generally through increased expression of its core
effectors, but there may also be more specific alterations in the expression of individual target genes. At the molecular level, this fine-tuning of
oncogenic signalling can occur through multiple mechanism including genetic and epigenetic alterations, changes in the abundance of
transcriptional cofactors and post-transcriptional modulation of gene products. Non-cell autonomous factors, whereby signalling is regulated
through interaction with stromal components and extracellular matrix, can also modulate the strength of oncogenic signalling in cancer cells and
consequently increase metastatic fitness.
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changes in the epigenetic landscape. In a mouse model of
small cell lung cancer, the activation of a single transcription
factor can induce widespread alterations in chromatin acces-
sibility in association with metastatic progression (Denny
et al., 2016). Similar mechanisms could activate metastasis
genes in other cancers as well.
The general concept of qualitatively and quantitatively
altered oncogenic signalling output as a driver of metastatic
progression is supported by multiple levels of evidence
beyond epigenetic transcriptional modulation. First, the lack
of mutations specifically associated with metastatic progres-
sion indicates that the activation of general oncogenic path-
ways usually takes place at a pre-metastatic stage of tumour
development (Vogelstein et al., 2013). Second, several micro-
RNAs and other mRNA modulatory factors have been func-
tionally linked to metastatic progression (Fish et al., 2016;
Goodarzi et al., 2014; Pencheva and Tavazoie, 2013;
Vanharanta et al., 2014). Rather than activating specific path-
ways, post-transcriptional regulation of mRNA abundance
would also fine-tune the transcriptional output of already
activated cellular signalling networks. Finally, several non-
cell autonomous mechanisms of metastatic cancer progres-
sion described inmultiple model systems lead to hyperactiva-
tion of one or more of the core oncogenic pathways in the
metastatic cell (Oskarsson et al., 2014). For example, interac-
tions between breast cancer cells and stromal components
can amplify survival signals downstream of Akt in severalPlease cite this article in press as: Patel, S.A., Vanharanta, S., Epige
http://dx.doi.org/10.1016/j.molonc.2016.09.008metastatic contexts (Chen et al., 2011; Zhang et al., 2009), but
the pathway is often activated already in primary breast tu-
mours (The Cancer Genome Atlas Network, 2012).9. Future perspective
Instead of through the activation of specific metastasis path-
ways, themetastatic phenotype seems to be acquired through
complex fine-tuning of the amplitude and target gene spectra
of the core pathways that drive tumour initiation and early
progression. Some of these pathways are activated by muta-
tions, others by non-mutated lineage factors. In this context,
epigenetic alterations do not drive cancer progression but
rather facilitate the establishment of themost aggressive phe-
notypes via selection. Themetastatic potential is a continuum
and it is acquired by multiple independent alterations in a
process akin to genetic evolutionary tinkering (Jacob, 1977).
However, even though the processmay be random, this epige-
nomic tinkering tends to follow similar evolutionary paths in
different tumours of the same tissue of origin, as is evidenced
by the shared transcriptional patterns associated with meta-
static progression in different patients and experimental sys-
tems. In this model, the intrinsic metastatic fitness of a given
cell is dictated by the combined net effect of all the active
pathways in that cell. It may therefore be difficult to precisely
determine the stage of tumour progression at which the met-
astatic phenotype is acquired: some metastasis genes may benetic determinants of metastasis, Molecular Oncology (2016),
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 6 ) 1e1 610activated early and others late. Despite this concept of meta-
static progression being supported bymultiple lines of clinical
and experimental evidence, several open questions remain:
i. In addition to changes in DNA methylation, which clearly
can allow a transcriptional regulator to access new target
loci, the general mechanisms through which active onco-
genic programmes are modulated during metastatic pro-
gression remain unknown. For example, can alterations
in higher order chromatin structure promote metastasis?
What is the role of transcriptional enhancers in metastatic
progression?
ii. Some chromatin regulators, such as the PRC2 complex, act
as buffers that stabilize transcriptional programmes and
consequently cell fates. Reduced PRC2 function could thus
promote metastatic progression indirectly by increasing
transcriptional variability from which aggressive clones
could emerge. Transcriptional variability has been linked
to higher likelihood of metastatic relapse (Nguyen et al.,
2016). However, the origins of transcriptional noise that
support metastatic progression remain poorly understood.
iii. The tumourmicroenvironment is an integral player in can-
cer progression and several examples of pro-metastatic
cancer-stroma signalling loops have been identified. Stro-
mal signals can also direct selection towards metastasis
(Zhang et al., 2013). Whether or not transient microenvi-
ronmental cues are able to stably reprogramme cancer
cell transcriptomes remains unclear, however.
iv. Mutations in several enzymes can change the metabolic
milieu in cancer cells. This has been linked to widespread
alterations in DNA methylation, as exemplified by IDH1
mutations in glioblastoma (Turcan et al., 2012). The contri-
bution of other metabolic alterations to epigenetic control
of cancer progression remains largely unexplored. Could
therapeutic perturbation of metabolic pathways modulate
cancer cell transcriptomes and consequently affect the
probability of metastatic progression?
v. Developmental genetic programmes are remarkably
robust, faithfully recapitulating complex phenotypes. Can-
cers, on the other hand, seem to benefit from genetic and
epigenetic instability. It would be important to know,
what kind of consequences does epigenetic instability
have on cancer cell fitness. Does it only increase plasticity
or could it also lead to vulnerabilities that could be
exploited therapeutically?
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